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The mammalian target of rapamycin inhibitors are normally favored as immunosuppressant agents for solid organ
transplantation such as kidney, liver or heart. Only in recent years have they been increasingly administered for the
treatment of neuroendocrine tumors. Even though mammalian target of rapamycin inhibitors are known to exhibit
specific side effects, everolimus-related severe hepatic steatosis has not as yet been described in the literature. We
report the case of a 76-year-old man who developed severe hepatic steatosis within four weeks of treatment with
everolimus as concomitant tumor therapy for a progressively growing neuroendocrine carcinoma of the ileum. A
diagnosis of hepatic steatosis was established using computer tomography and fibroscan©. Other underlying causes
for steatosis hepatis could be excluded. Further studies are warranted to explain the underlying mechanisms.Background
In recent years new cancer treatments have been devel-
oped [1,2]. Everolimus is an inhibitor of the mammalian
target of rapamycin (mTOR) and has been approved for
the prevention of organ transplant rejection as well as
for the treatment of subependymal giant cell astrocy-
toma, neuroendocrine tumors, renal cell carcinoma and
breast cancer [3-8]. mTOR inhibitors are increasingly
administered for the treatment of neuroendocrine tu-
mors [9,10]. The most frequent everolimus-associated
adverse effects include myelosuppression, which may
result in anemia, thrombo- and lymphocytopenia, and
subsequent complications such as infections [4]. Non-
infective pneumonitis, pleural or pericardial effusions,
elevated transaminases, hyperlipidemia, electrolyte disor-
ders, edema, hypertension, gastrointestinal symptoms
and renal failure including proteinuria are also observed
[11]. Here, we report a case of severe hepatic steatosis
following everolimus therapy in a patient with a neuro-
endocrine tumor of the ileum.
Case presentation
A 76-year-old male patient was diagnosed with a highly
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reproduction in any medium, provided the or(Ki67 15%) in November 2009, including liver metasta-
ses. In December 2009 he underwent a segmental resec-
tion of the ileum and multiple (n = 23) atypical liver
resection (cherry picking) of segments II, III, IV, V, VI,
VII and VIII. In January 2010 he was discharged from
hospital, followed by a total of six monthly intravenous
applications of octreotide (Sandostatin©; 3 × 0.2 mg
subcutaneously). In July 2010, the patient developed a
recurrence of his liver metastases. Selective internal
radiotherapy was planned. After radiologic evaluation,
the duodenal branches of the right and left hepatic ar-
tery were surgically divided because of difficult interven-
tional access; selective internal radiotherapy treatment
was then performed. A magnetic resonance tomography
scan of his abdomen in October 2010 and a computed
tomography scan of his abdomen and thorax in February
2011 showed no signs of local cancer recurrence or dis-
tant metastasis.
In June 2011, magnetic resonance tomography of the
abdomen revealed a liver metastasis in segment V. In
addition, multiple bone metastases (9. left costae, os
sacrum, os ileum with iliosacral joint) were suspected on
a whole body scintigraphy with 200 MBq indium-111-
octreotide. The patient required surgery for a symp-
tomatic incisional hernia. Because the most dynamic
progression was seen in the liver, the liver lesions were
resected again (cherry picking) during the repair of thel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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streptozotocin (500 mg/m2 body surface) and 5-fluorouracil
(500 mg/m2 body surface) was initiated. In September
2011 a port catheter system was inserted. One month
later, after three cycles of streptozotocin, the patient de-
veloped aplasia accompanied by severe mucositis grade III
(CTC- scale) and chemotherapy had to be interrupted.
Nevertheless the tumor progressed further and the patient
was switched to (DOTA 0-Phe1-Tyr3)octreotide chemo-
therapy (also known as edotreotide) in January 2012. After
the development of distant metastases in the thoracic and
lumbar spine, a palliative radiotherapy of 30 Gy was ad-
ministrated from thoracic vertebra 12 to lumbar vertebra
4 in April 2012. In June 2012, everolimus treatment was
started (10 mg/day orally). Within four weeks the patient
developed severe ascites, accompanied by steadily rising
liver enzymes.
Before the start of everolimus treatment, the patient
had moderately elevated but stable triglyceride blood
levels (158 mg /dL) for many years. As he had a history
of coronary artery disease, he was on simvastatin treat-
ment and his cholesterol blood levels were stable around
120 mg/dL. Probably because of his liver metastases and
repetitive atypical liver resections with compromised
liver function, we observed low total protein levels (5.89
g/dL), low albumin levels (2.2 g/dL), elevated liver
enzymes (alanine transaminase (ALT): 58 U/=L, aspartateFigure 1 Pre-therapy and follow-up computed tomography images. (
(with region of interest measurements) shows multiple liver metastases tha
spleen parenchyma. (c,d) In the follow-up examination, a progress of the m
HU, Hounsfield units.transaminase (AST): 9 U/L, gamma glutamyl trans-
peptidase: 1.350 U/L), and an increased lactate de-
hydrogenase blood concentration (407 U/lL) shortly
before mTOR inhibitor treatment was started. At that
time direct bilirubin was within normal range (0.49
mg/dl). After four weeks of everolimus treatment, liver
enzymes increased (maximal ALT: 16 U/L, AST: 169
U/L, gamma glutamyl transpeptidase: 1599 U/L, lactate
dehydrogenase 571 U/L) while bilirubin levels stayed
within normal range. Viral hepatitis could be excluded
because hepatitis B surface antigen as well as hepatitis
B, C and E virus serology were negative. There were no
signs of diabetes: blood sugar tests, which had been
routinely taken during his hospital stays as well as his
visits to the outpatient clinics, were within normal
range. Furthermore the patient had no signs of meta-
bolic syndrome before receiving everolimus. At the
start of everolimus treatment, his body mass index was
26.3 kg/m2 and within the normal range (height 170
cm, weight 75 kg). He did not lose or gain weight rap-
idly before starting everolimus. Except for everolimus,
no other chemotherapeutic agent or new medication
was administered that could cause a fatty liver.
Because of the increased liver enzymes and abdominal
pain, computer tomography of the abdomen was per-
formed and revealed severe hepatic steatosis (Figure 1).
The diagnosis was confirmed by a fibroscan even thougha,b) The pre-therapy axial post-contrast computed tomography images
t were hypodense compared with the normal density of the liver and
etastases was noted and a diffuse abnormal low density of the liver.
Schieren et al. European Journal of Medical Research 2013, 18:22 Page 3 of 4
http://www.eurjmedres.com/content/18/1/22examination results were difficult to interpret due to diffi-
cult examination conditions (ascites and air). The hepatic
steatosis developed rapidly - the histopathology of the spe-
cimen obtained from the atypical liver resection in 2009
had not revealed any signs of liver steatosis at that time.
Even though everolimus treatment was stopped, the pa-
tient developed multiorgan failure eight weeks later and
died.
Conclusions
Even though everolimus has been described to cause
hepatic adverse events, including an increase in AST
(up to 25%), increased ALT (up to 21%) and increased
bilirubin (up to 3%), a rapid onset of severe hepatic
steatosis has not been reported in the literature. Causes of
rapid steatosis hepatis may include diabetes mellitus, pro-
tein malnutrition, hypertension, obesity, rapid weight loss
and sleep apnea. In addition, certain cell toxins such as
oxygen radicals and certain drugs are associated with
hepatic steatosis.
Our patient had a history of malnutrition. Neverthe-
less, total protein and albumin levels had been stable for
months. A history of alcohol consumption was ex-
cluded. There was no history of diabetes mellitus. Car-
diovascular disease had been stable for several years.
The patient received none of the drugs usually associ-
ated with non-alcoholic fatty liver disease. Viral hepa-
titis was also excluded. As the rapid onset of the clinical
features correlated strongly with the beginning of the
everolimus treatment, we propose that hepatic steatosis
in our patient was caused by everolimus.
One might speculate upon the mechanism by which
everolimus could induce hepatic steatosis beside a dir-
ect toxic effect. Osawa et al. reported that rapamycin
attenuated hepatocyte lipid accumulation induced by
fatty acid with serotonin, suggesting a rather protective
role of mTOR inhibition in this setting [12]. Molecular
and cellular mechanisms of steatosis hepatis have not
been fully elucidated, but insulin resistance has been
discussed as a possible key mechanism. Chronic admin-
istration of the mTOR inhibitor rapamycin has been
shown to substantially impair glucose tolerance and in-
sulin action, inducing muscle insulin resistance despite
weight loss in rats [13]. Lamming et al. demonstrated
that this effect is probably mediated by disruption
of a second mTOR complex, mTORC2, which is re-
quired for the insulin-mediated suppression of hepatic
gluconeogenesis [14]. A similar mechanism may be
responsible for the induction of steatosis hepatis in
our patient. In this scenario, the pre-existing impaired
liver function and malnutrition might have promoted
the development of everolimus-induced steatosis hepa-
titis. Additional studies are needed to clarify the
pathomechanism involved.With regard to the steadily increasing indications for
everolimus therapy, treating physicians should be aware
of the potential adverse effect of rapid and severe
steatosis hepatis in patients with pre-existing liver
disease.
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